Flow cytometry analysis revealed that 15–20% of splenic CD8 T cells were antigen-specific using both prime-boost approaches (Fig. 2e), further confirming that MRB co-administered with an antigenic peptide is as effective at boosting anti-tumor immunity as MRB encoding the same antigen. Here, ROBO4 is linked to neoplasm.